(0.58%) 5 075.75 points
(0.33%) 38 195 points
(0.79%) 17 575 points
(0.94%) $79.74
(2.38%) $1.978
(0.23%) $2 316.20
(-0.20%) $26.70
(1.06%) $965.00
(0.12%) $0.934
(0.30%) $11.06
(0.02%) $0.799
(-1.42%) $91.94
Live Chart Being Loaded With Signals
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases...
Stats | |
---|---|
本日の出来高 | 7.91M |
平均出来高 | 9.33M |
時価総額 | 67.91B |
EPS | HKD0 ( 2024-03-25 ) |
次の収益日 | ( HKD0 ) 2024-06-20 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -58.94 |
ATR14 | HKD0.0440 (0.10%) |
ボリューム 相関
Innovent Biologics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Innovent Biologics Inc 相関 - 通貨/商品
Innovent Biologics Inc 財務諸表
Annual | 2023 |
収益: | HKD6.21B |
総利益: | HKD5.07B (81.69 %) |
EPS: | HKD-0.660 |
FY | 2023 |
収益: | HKD6.21B |
総利益: | HKD5.07B (81.69 %) |
EPS: | HKD-0.660 |
FY | 2022 |
収益: | HKD4.56B |
総利益: | HKD3.63B (79.57 %) |
EPS: | HKD-1.460 |
FY | 2021 |
収益: | HKD4.27B |
総利益: | HKD3.70B (86.58 %) |
EPS: | HKD-2.31 |
Financial Reports:
No articles found.
Innovent Biologics Inc
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。